Indian Pharma Within Global Reach?

The Indian pharmaceutical industry is presently going through a phase of transition and potential consolidation, owing to India's new TRIPS-compliant intellectual property regime and other rules aimed at enhancing the industry's credibility nationally and internationally. Appropriate policy interventions can play a large role in cushioning the transition (and gradual consolidation) of the industry post-2005. Using firm level data collected in 2004-2005, this paper seeks to make two major contributions in this regard. The research findings show that the Indian pharmaceutical sector is a heterogeneous mix of firms with vast differences in innovative capabilities. Based on these differences, the groups can be categorized into specific "innovation modes" (the innovator, the niche operator and the manufacturer), each mode being a step closer towards the innovative pharmaceutical firm. Second, the paper highlights how the emerging strategies of firms in all three groups, although different, underpin the importance of systemic coordination in the pharmaceutical sector. The analysis links both these findings to policies pursued in the pharmaceutical sector over the past four decades and highlights the role of differential innovation policy in ensuring optimal sectoral performance.Pharmaceutical industry, Innovation policy, TRIPS, Intellectual Propery, IPR, Property rights, India

India's product patent protection regime: Less or more of "pills for the poor"?

The year 2005 marks the end of transition period for many developing countries with competent pharmaceutical sectors that competed in supplying generic versions of patented drugs to LDCs before, thereby inducing price competition and enhancing access to medicines. In a post-2005 scenario, the critical issue is whether LDCs without adequate manufacturing capabilities can make use of compulsory licensing expeditiously to induce price competition and secure lower prices. This paper uses empirical evidence collected during a firm-level survey of the Indian pharmaceutical sector to generate evidence on emerging strategies of firms. It shows that the vigour of compulsory licensing as a price-leveraging instrument post-2005 is incumbent mainly on its economic feasibility. It shows that Indian firms view the market potential (in terms of market size and profits involved in such supply, especially if they have to make specific technological investments to produce the drug) of the mechanism much more severely than before, and may be less inclined to engage in such production if their commercial expectations are grossly unmet. The analysis assesses implications of emerging strategies of firms in the Indian pharmaceutical sector for access to medicines both domestically and internationally, and highlights the challenges involved.product patents, Indian pharmaceuticals, generics, access

Rough Road to Market: Institutional Barriers to Innovations in Africa

Translating R&D and inventive efforts into a market product is characterized by significant financial skills, and the ability to overcome technical and instititonal barriers. Research into and translation of new technologies such as biotechnology products to the market requires even greater resources. This paper aims to understand the key factors that foster or hinder the complex process of translating R&D efforts into innovative products. Different pathways exist in developed countries such as firm-level efforts, the use of IPs, the spin-off of new firms that develop new products, or a mixture of these. Developing countries differ substantially in the kinds of instruments they use because of their considerably weaker institutional environment and for this reason our framework takes a systemic and institutional perspective. The paper comtributes to this issue by examining systemic institutional barriers to commercializing biotechnology in a develping context within a systems of innovation framework.research and development, biotechnology, commercialization, innovation, Africa, learning, institution building

Dry heat disinfection versus seed borne Fusarium – six years of practical experience

Non-Peer Reviewe

Functional and molecular characterisation of two stomatin-like proteins from Arabidopsis thaliana

Stomatins belong to the band-7 (or SPFH domain) family (short for Stomatin, Prohibitin, Flotillin HflC/K) of diverse membrane proteins. This protein family is evolutionary conserved with members found in all sequenced eukaryotes and in most prokaryotes. Band-7 family proteins have the ability to oligomerise and generally aid in the assembly and regulation of large membrane-bound protein complexes. In animals, stomatins have been demonstrated to regulate ion channels by direct protein interactions. Additionally, they localise to membrane microdomains where they actively contribute to their assembly by binding sterols, and they also associate with the actin cytoskeleton. The Arabidopsis genome encodes for two structurally similar stomatin-like proteins that are functionally completely unknown yet. They will be referred to as AtSlp1 (for Arabidopsis thaliana stomatin-like protein) and AtSlp2. The aim of this thesis was to provide a detailed characterisation of these two genes on a molecular and functional level. Both proteins are expressed ubiquitously throughout plant development, but they accumulate at particularly high levels in pollen and other metabolically active cells. Phylogenetic analysis reveals that AtSlps are homologous to stomatin-like proteins of type 2. Amongst these, the human stomatin-like protein 2 (HsSlp2) is localised to mitochondria where it participates in large membrane-bound protein complexes and is also involved in the proliferation of cancer cells. Evidence is provided here that demonstrates mitochondrial localisation of both Arabidopsis Slp proteins in vitro and in vivo. On a functional level, mitochondria from an slp1 knockout mutant plant have a decreased mitochondrial membrane potential and increased oxygen consumption rates. This is interpreted as a defect in coupling efficiency and an impairment of the mitochondrial inner membrane integrity. This defect results in a variety of other growth phenotypes that are related to metabolically active tissues and cell types. Knockout plants are delayed in overall growth of shoots and roots and have decreased seed germination rates. Additionally, these plants are less resistant to conditions of high salinity and are less fertile. Overexpression of a protein acting as a putative dominant-negative Slp fragment results in plants with a dwarf phenotype and early onset of leaf senescence. This phenotype correlates with increased levels of reactive oxygen species and altered organelle ultrastructure. Guard cells from these plants in particular have enlarged chloroplasts and are impaired in transpirational control. It is concluded that also in plants, stomatins act together with other band-7 family proteins as parts of large protein complexes that have regulatory roles important for development and stress responses. Their main role is probably to provide membrane scaffolds that affect mitochondrial function and morphology during cell division and in situations of mitochondrial stress

On the Cultural Power of the “Marianas Web” Meme

Explores the Marianas Web meme as a cultural myth. Special appearance by Rudy Giuliani

Archives for the Dark Web: A Field Guide for Study

This chapter provides a field guide for other digital humanists who want to study the Dark Web. In order to focus the chapter, I emphasize my belief that, in order to study the cultures of Dark Web sites and users, the digital humanist must engage with these systems' technical infrastructures. I will provide specific reasons why I believe that understanding the technical details of Freenet, Tor, and I2P will benefit any researchers who study these systems, even if they focus on end users, aesthetics, or Dark Web cultures. To this end, I offer a catalog of archives and resources researchers could draw on and a discussion of why researchers should build their own archives. I conclude with some remarks about ethics of Dark Web research